Showing posts with label Early Detection. Show all posts
Showing posts with label Early Detection. Show all posts

The Pathological Cascade of Alzheimer's Disease

By the time you show symptoms of Alzheimer's disease, many irreversible changes have already occurred in your brain. This explains why early detection and timely intervention are so important. As described by the pathological cascade summarized in this post, treatment should ideally begin long before symptoms appear.  

The key features of the Alzheimer's disease pathological cascade include the accumulation of two types of abnormal proteins in the brain: amyloid beta (Aβ) plaques and tau tangles. The Aβ plaques are formed by the accumulation of a protein called amyloid beta, which is produced by the breakdown of a larger protein called amyloid precursor protein (APP). The tau tangles are formed by the abnormal accumulation of a protein called tau, which is essential for the normal functioning of the brain's nerve cells.

The accumulation of Aβ plaques in the brain disrupts the normal communication between brain cells and leads to inflammation and the activation of immune cells. As the disease progresses, tau proteins also start to accumulate in the brain, forming tangles that further contribute to the degeneration of brain cells. 

A simplified view of the process, which may take years, looks like this:
Protein Accumulation >> Inflammation >> Cell Death >> Symptoms

In an ideal scenario, patients would begin a regimen of disease modifying therapy (currently approved treatments can remove amyloid protein from the brain) as soon as amyloid plaques and tau tangles are present, and before inflammation, cell death, and cognitive symptoms emerge. 

Achieving such timely intervention on any meaningful scale will require a proactive mindset toward managing cognitive health along with inexpensive and non-invasive methods for detecting the early stages of the disease. Fortunately, such methods are now becoming available. One promising approach, from Embic Corporation, involves a brief cognitive test with sophisticated scoring that quantifies the unobservable cognitive processes of encoding and retrieval. These processes underly nearly all cognitive function and show clear changes in Alzheimer's patients long before symptoms of memory loss appear.

The good news is that the science of managing Alzheimer's disease, from detection to diagnosis to treatment, is moving forward quite rapidly. The bad news is that progress is happening faster than the healthcare system can embrace. Researchers need to keep racing forward and the care system needs to catch up!

Alzheimer's Cure by 2025: An Unnecessary Goal?


Contributed by: Dennis Fortier, President, Medical Care Corporation

The National Alzheimer's Prevention Act, signed into law one year ago, calls for a national strategy for defeating this terrible disease. A late-stage draft of the strategy sets a goal to develop a cure by the year 2025.  While many have suggested a timeline with more urgency, say by 2020, others have suggested that this timeline is too ambitious.

On the one hand, given our still poor understanding of the disease, coupled with a dismal track record of success for pipeline drugs over the past decade, it seems unlikely that a cure could be developed prior to 2025.  In fact, against the backrop of recent evidence, it may well take longer than that.

On the other hand, we could stop short of a cure and still have great success.  For example, many chronic diseases like diabetes and hypertension have no cure, but we have effective treatments, and we manage those diseases with high efficacy.  It is likely that new drugs, developed well before 2025, will give us greater treatment benefits for patients with Alzheimer's.

Perhaps of greater importance is the fact that we already have approved therapies that can significantly slow Alzheimer's disease progression.  However, since we commonly detect the disease too late and intervene only after massive brain damage has occurred, the perception among physicians is that treatment is unhelpful.  This nihilistic perception actually perpetuates the cycle of late intervention because, believing that there is no treatment, many MDs don't look for early signs Alzheimer's.

In this regard, a key element to an effective national Alzheimer's strategy would be to update physicians about the benefits of early detection and equip them with the tools and training to proactively monitor the cognitive health of their patients.  When a cure is developed, that will be great.  But in the meantime, we can find the disease early and treat it as effectively as possible with robust therapy (drugs, diet, physical exercise, control of diabetes and hypertension, intellectual stimulation, social engagement, and caregiver education).  Such a comprehensive approach has been shown to significantly delay disease progression in a meaningful percentage of early-stage patients.

World Alzheimer's Report 2011

Contributed by: Dennis Fortier, President, Medical Care Corporation
_______________________________________________________

Alzheimer's Disease International is the federation of national "Alzheimer's associations" around the world.  Each year, they compile a world report summarizing the state of scientific knowledge in the field of Alzheimer's disease.

This year's version, World Alzheimer's Report 2011, was released last week.  You can use these links to download the Executive Summary or download the Full Report.

The highlight of this year's report is encompassed in its subtitle: The Benefits of Early Diagnosis and Intervention.  This is an important message that is undermined daily by the mantra of the popular press, where messages about the futility of treatment are persistent. In this summary of scientific evidence, vetted by some of the world's greatest experts in this field, it is clear that detecting AD at an early stage and adhering to a robust regimen of treatment, can have tremendous health and economic benefits.

I am happy to see this report's strong and optimistic emphasis on such a positive side of the story.  I hope you will join me in sharing this report as broadly as possible by passing it along to your online networks.

Blood Test for Diagnosing Alzheimer's: A Major Leap Forward?



Contributed by: Dennis Fortier, President, Medical Care Corporation

________________________________________________


With so many of the news stories I summarize here, I include caveats about the long and arduous path that basic science must travel before a clinically beneficial advance becomes available to the public. The same caveat applies to the heavy coverage of a new, blood-based diagnostic test recently developed by the Scripps Research Institute and published in the January 7 issue of Cell.

Having said that, this scientific approach strikes me as one worthy of the frothy press it has already spawned.

The approach is exciting in its novelty. Rather than identifying the specific antigens that cause an immune response (production of antibodies) at early stages of a particular disease, and then screening the blood for the presence of those antibodies, the Scripps researchers took another path. They skipped the step at which conventional science is currently focused. That is, they did not bother with the daunting challenge of identifying which specific antigens might stimulate an immune response to fight in early stage Alzheimer's disease.

Rather, in their study, they loaded the blood with thousands of synthetic molecules designed to bind to antibodies of all sorts. By then analyzing the results from patients with Alzheimer's compared to those with Parkinson's and those deemed "healthy", they detected clear evidence that Alzheimer's patients had a much higher concentration of two particular antibodies in their blood. The conclusion, which must be validated with more data, is that these two antibodies are bio-markers for early-stage Alzheimer's disease.

This may prove to be extremely valuable in detecting early stage disease presence, but may pay other dividends as well. If these antibodies do indeed indicate a response to Alzheimer's pathology, then this study may also shed important, new light on the actual disease process which, in turn, could accelerate research on new treatments

Obviously, there is much science to conduct before the world can benefit from this research. But the prospect of leap-frogging one nagging problem in the process, the identification of specific antigens that indicate Alzheimer's, is an exciting proposition.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Combining a Brain Scan with a Spinal Fluid Test


Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

According to a study published in the latest issue of Archives of Neurology, researchers at University College London's Institute of Neurology have collected evidence of a correlation between two interesting brain pathologies. The research looked at low levels of beta-amyloid in the spinal fluid and, based on an MRI brain scan twelve months later, the rate of brain atrophy (or shrinkage).

The interest in this study stems from prior research showing that a low level of amyloid in the cerebral spinal fluid (CSF) is a common (but not certain) precursor to Alzheimer's disease. Furthermore, typical Alzheimer's pathology includes the death of brain cells leading to brain shrinkage. Therefore, noting that these two indicators seem to move in unfavorable directions, even before symptoms are present, might lead to methods for earlier detection and intervention.

In general, the expert research community supports the notion of combining indicators to detect early trends that should be carefully monitored. While this study is certainly noteworthy, coverage in the media, that has portrayed these findings as a method for detecting early stage Alzheimer's disease, is probably over-stated at this early point.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Does Early Diagnosis of Alzheimer's Really Create an Ethical Dilemma?


Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

Does early diagnosis of Alzheimer's really create an ethical dilemma?

For all of the press devoted to scrutinizing the pros and cons of delivering an Alzheimer's diagnosis to a patient with only mild symptoms, including a front page article in today's NY Times, it is easy to overlook the question posed above. In fact, anyone could be forgiven if they assumed, based on the constant characterization in the press, that a dilemma is at hand.

The Dilemma That Isn't

Posing this question may generate provocative headlines and robust debate but, if we step back and consider the larger context, there really is no dilemma. We do not need any ethicists to ponder and rule on this question because it doesn't require a single, universal answer.

Some people seek clinical information and get comfort from having it available, even when the information consists of bad news like an Alzheimer's diagnosis. Others prefer ignorance when new information will cause them to worry needlessly about a situation they cannot change.

Patients Choose
Rather than debating which approach is better and pronouncing the presence of a dilemma, all we need to do is let individuals choose their preference. Those who want to know should be told; those who do not want to know, needn't have the information thrust upon them. When someone has a sign or symptom of a medical problem and then seeks a physician's opinion about the underlying problem, they are pretty much declaring that they want a diagnosis. In the real world, the "want-to-know vs. don't-want-to-know" decision is made by either consulting a physician or not.

This situation is not as black and white as described here, but it certainly is far less gray than characterized by the press. In general, people seeking medical attention for a cognitive complaint want help and physicians have an obligation to diagnose the problem and treat it as effectively as possible.

Sometimes this will involve giving patients news they would rather not hear, but the symptoms and the angst that comes with those symptoms, are already a reality in the patient's lives. A definitive diagnosis reduces uncertainty and helps the treatment process move optimally forward.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Non-Clinical Benefits of Early Detection of Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

In this short video from PBS, the National Alzheimer's Association's Medical Director, William Thies summarizes the non-clinical benefits of getting an early diagnosis of Alzheimer's disease.

He doesn't touch on the emerging evidence that treatment, even with currently approved medications, may also have greater benefits at an earlier stage of disease progression when the brain is still quite healthy. The extent of such treatment benefits is generally moderate but, for some patients, it can be quite meaningful.

William Thies, Ph.D., Chief Medical and Scientific Officer, Alzheimer’s Association

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Early Detection of Alzheimer's is Best

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________
This article from Voice of America bears an important headline: Early Diagnosis of Alzheimer's Better for Patients and Caregivers. That's a message we promote vigorously in this blog.

The article itself is not based on any particular new findings or recently published research. It is merely a summary of aggregated conclusions and an important reminder that we often intervene late. When we do so, we lose an opportunity to treat AD at an early stage when minimal brain damage has occurred. This then leads to therapeutic nihilism and the ongoing, but incorrect belief, that attempting to treat Alzheimer's disease is futile.

I highlight this today as a reminder about the importance of early detection.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Revised Definition of Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

With a publication slated for the November issue of Lancet Neurology, the International Working Group for New Research for the Diagnosis of AD has updated their position paper from 2007. In the new publication, they suggest that AD should be defined as impaired episodic memory plus one bio-marker (either MRI, PET, or spinal fluid) indicating known disease pathology.

Importantly, the presence of dementia would no longer be required as part of the new definition of Alzheimer's disease. This will allow physicians to diagnose the disease and intervene with therapy at an earlier stage of symptoms.

As we have discussed here often, the current practice of late diagnosis, which is driven in many ways by the old definition requiring dementia, is a major obstacle to effective treatment.

This recommendation is in line with similar proposals from US expert panels and bodes well for future advances in this field.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

How to Best Detect Early Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

Sometimes, a lot of press coverage is devoted to an interesting misinterpretation of a fact that, once correctly understood, is not nearly as interesting. This is one of those times.

Over the past week, I have seen intense coverage of a story about how friends and family are better at spotting early signs of Alzheimer's dementia compared to traditional tests that a doctor might use. This sounds great until you unpack the headline and understand the facts.

Even Mild Dementia is a Severe State of Health
The problem, as we point out often in this space, is the definition of "dementia". Even mild dementia, which sounds like a subtle condition, is actually a severely impaired state of mental health. To meet the definition of dementia, even mild dementia, a patient must be so impaired that their loss of function interferes with their occupational or social life. Demented people, even mildly demented people, cannot completely care for themselves.

Detecting Dementia does not Require a Test
With this is mind, many experts make the case (and I agree with them), that a test for dementia is not necessary. Dementia is a readily apparent condition that a friend or family member should easily recognize. The fact that doctors still use tests that cannot accurately distinguish between a demented person and a non-demented person is indicative of ineffective clinical practices.

For the record, there are newer, more accurate tests, such as the MCI Screen, that detect dementia with almost perfect accuracy. More importantly, they also identify much earlier and subtler stages of decline known as mild cognitive impairment. However, this current finding from Washington University and published in Brain, compared the ability of friends and family at spotting spot Alzheimer's dementia with the accuracy of "traditional" tests. This is a clear and damming comment about the poor accuracy and minimal utility of the "traditional" test they used for comparison, the Mini-Mental State Exam (MMSE).

In this study, input was collected with an instrument called the AD8, an eight item questionnaire that is completed, on behalf of the patient, by an informant (friend of family member). It was shown to be better at identifying demented patients than the MMSE. That is great news and the AD8 is a non-invasive tool that would be a pragmatic improvement over the MMSE in a primary care setting.

The Bottom Line
I think the most important message, buried in this recent spate of press, is that the traditional tests are not as good as the AD8 at detecting dementia, but detecting dementia doesn't really require a test. To intervene early against Alzheimer's disease, and to reassure healthy patients that their perceived memory decline is not caused by underlying disease, physicians need instruments that accurately detect mild cognitive impairment.

Advances in detecting dementia are not interesting stories, regardless of how much press they get.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

The Most Immediate and Practical Use for an Alzheimer's Diagnostic Test

Contributed by: Dennis Fortier, President, Medical Care Corporation

Sometimes, a debate is framed in such a way that important perspectives are under-emphasized if not completely overlooked. I think this is the case in the spirited debate about if and when we should use biomarkers to help diagnose Alzheimer's disease.

I can understand that many young, healthy people would prefer not to know that Alzheimer's lurks with certainty in their future. That whole discussion is important but perhaps off-point. Here is what we should not overlook.

An increasing number of people are expressing memory complaints to physicians on a daily basis. Some are depressed, some have early stage AD, some have had a small stroke, some have a thyroid disorder, and among the others, many are perfectly healthy but correctly perceiving changes associated with their advancing age. It is the physician's job to accurately diagnose any underlying medical conditions and to treat them. In these cases, an accurate test for Alzheimer's disease has great value.

The published research in this area is clear. A great many AD patients go undiagnosed and untreated for many, destructive years as their doctors grapple with an uncertain diagnosis. Others are treated for Alzheimer's disease based on an educated guess, when in fact their true condition could have been more effectively (and perhaps less expensively) treated had the diagnosis been correct.

I do not suggest that we run out and test people with no symptoms of cognitive decline. I do suggest that a great many patients and their doctors will benefit enormously when a commercially viable diagnostic test for AD is available.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Ethical Dilemma: Who Should Test For Alzheimer's?

Contributed by: Dennis Fortier, President, Medical Care Corporation

Is this really a dilemma?

Researchers have devised what seems to be a highly accurate test to identify the signature proteins of Alzheimer's disease in spinal fluid. In a publication about the test in this month's Archives of Neurology, the test showed perfect accuracy in patients known to have Alzheimer's disease.

One particular application of this technology could have great clinical utility. When aging patients present to their physician with memory loss, the physician must consider many possible causes of the problem before prescribing treatment. In some instances, the physician can find an obvious culprit such as stroke, depression, or a number of metabolic conditions. In other instances, the diagnosis is less clear. This new test might add much needed clarity to the diagnostic process for identifying Alzheimer's disease. This will help get AD patients on proper treatment in a timely manner while preventing others, who might otherwise be misdiagnosed with AD, from receiving wrong treatment.

Some more difficult questions about the value of this new test have arisen from the fact that, in the study, the test showed that about one third of subjects who had no symptoms of memory loss, also had the signature proteins in their spinal fluid. One interpretation is that these subjects have early stage pathology and will eventually develop the symptoms. This has given rise to the dilemma: Who should get tested and what should we do with those who test positive?

I would argue that this question, which is framed in terms of the entire population, poses no dilemma at all if you frame it at the individual level. Those who wish to inform themselves about risks in their future, so as to prepare themselves legally, financially, and spiritually, as well as to engage in life style modifications that could prolong health, should be free to have a test and learn what they can. Those who prefer not to know should be allowed that option as well. There are compelling arguments on either side.

As our understanding of the disease and our ability to treat it improve, the "find out early" side of the argument will be generally adopted by the masses and no debate will remain. In the meantime, there is no need to persuade everyone to accept one approach or the other. Those who prefer information should have access to it, while those who prefer ignorance should be allowed their bliss.

In a well-written summary of the ethical questions surrounding this science, bio-ethicist Jonathan D. Moreno commented on this development in The New Republic.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Predicting Alzheimer's Disease with Spinal Fluid

Contributed by: Dennis Fortier, President, Medical Care Corporation

For some years now, the research community has been intensively investigating bio-markers to help diagnose Alzheimer's disease at an early stage while the symptoms are still subtle and minimal brain damage has occurred. It is hoped that bio-markers progressing in advance of symptom progression will also be useful in understanding the disease and in unlocking the secrets of effective treatment.

There is massive press this week (NYTimes, CNN, WebMD, LATimes) on a new study published in the Archives of Neurology. The study shows that protein levels in the spinal fluid are useful in diagnosing Alzheimer's disease, even in subjects with mild memory deficits that would not meet today's criteria for a diagnosis of Alzheimer's disease. This is good news and bodes well for ongoing efforts to understand and treat this debilitating disease.

Interestingly, this finding also adds importance to another debate that has been recently prominent in the press. The debate concerns the utility of new proposed guidelines that would define Alzheimer's disease based on the presence of mild symptoms plus pathology as opposed to the current guidelines which require severe symptoms (dementia) before making the diagnosis. What began as a hypothetical (if we had a good bio-marker, would we consider subtle memory loss plus a positive indication from the bio-marker as a conclusive indication of AD?) has now become a more concrete and more urgent question.

Personally, I side with the growing consensus of experts who believe that memory loss, when coupled with a bio-marker known to be associated with AD (hippocampal atrophy, amyloid plaques, or now, signature proteins in the spinal fluid), should be diagnosed as Alzheimer's disease and treated accordingly if other common causes of memory loss (depression, thyroid, vitamin deficiency, etc.) have been ruled out.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Early Detection of Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

It has been a long time coming but the the press and the general public are finally beginning to grasp the benefits of detecting Alzheimer's disease at an early stage.

A publication this week in the Archives of Neurology described a highly accurate test of spinal fluid for definitively diagnosing the pathology we associate with Alzheimer's disease. While the debate about "when the disease begins" will continue to rage (does it begin at the onset of definitive pathology or at the onset of symptoms?), a consensus has emerged that earlier detection is better.

Regular readers of this blog know that I am often flabbergasted at what I consider to be negative interpretations of scientific advance, superficial skepticism about progress, and nihilism with regards to our overall ability to combat dementia in an aging population. However, the press this week around this new diagnostic approach has been very positive.

As a case in point, this brief editorial posted today in the New York Times makes a cogent argument supporting early detection and diagnosis of Alzheimer's disease. While many cling to the outdated dogma that, until a cure is found, it is better "not to know", recent scientific advances and some progressive thinking are ushering in a new paradigm.

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Tests to Identify Alzheimer's Disease



















Contributed by: Dennis Fortier, President, Medical Care Corporation

________________________________________________

This post starts with a disclosing reminder that I work for Medical Care Corporation, a company focused on developing assessment technologies aimed at helping physicians evaluate patients with memory concerns. As such, I pay close attention to developments in the cognitive testing space.

Two New Tests
I have noticed several news items recently on two interesting new instruments: the Five-Word Test (5WT) and the Computer Self Test (CST). A study on the 5WT was presented in Thessaloniki, Greece at the 25th Annual Conference on Alzheimer's Disease (ADI). Research on the accuracy of the CST was published in the Journal of Alzheimer's Disease.

These stories are news worthy because Alzheimer's disease is routinely diagnosed at a very late stage of progression when treatment is fairly ineffective. As such, earlier intervention is currently our best opportunity to improve treatment efficacy. Developing brief and accurate assessment technologies for use in primary care settings could facilitate a great advance in standards of care for aging patients with memory concerns.

Daunting Challenge: Ensuring Clinical Utility
The biggest hurdle is, to make medical, economic and logistical sense, a tool for clinical use must satisfy some daunting criteria that seem to work against one another.

For example, the tool must be highly accurate if used in assisting medical decisions but must also be very brief since primary care physicians are limited in the time they can spend with each patient. The best way to improve accuracy is to add items to a test battery but doing so increases the time requirement for administration which is problematic.

Additionally, the tool must be simple enough to facilitate easy adoption but sophisticated enough to qualify for reimbursement by major insurance payers. This is another challenging trade-off. As we all know, most physician's practices are small businesses and cannot absorb the costs of additional procedures, particularly those that require specialized knowledge and staff training, if they are not paid to conduct these new procedures. All told, developing a clinically effective tool is a tricky and elusive proposition.

Detecting "Dementia" is Too Late
The 5WT and the CST seem to outperform common instruments like the Mini Mental State Exam (MMSA) and the Montreal Cognitive Assessment. Both of these common tests have a purpose but neither has been shown useful in detecting pre-dementia stages of memory loss. Therefore, outperforming them does not necessarily imply clinical utility in detecting subtle memory loss. In fact, the research on the 5WT and the CST was designed to verify accuracy in identifying "dementia".

As we have written here often, dementia is a descriptive term for a fairly severe degree of impairment (a demented person has lost such a degree of mental function that they can no longer care for themselves). Considering this, a tool for identifying dementia does not enable earlier intervention against Alzheimer's disease as, in fact, it is in the dementia stage that primary care physicians are currently intervening. As most physicians will tell you, once a patient is demented, no test is required to determine that something is wrong.

Detecting Mild Cognitive Impairment
To improve standards of care, we need tools that separate healthy aging from more subtle stages of memory loss so that physicians can diagnose an earlier stage problem and treat it before it progresses and causes irreparable damage. According to the peer-reviewed medical literature, the most accurate assessment technology suitable for clinical use is the MCI Screen. It is brief, simple, and accurate in detecting the earliest stages of subtle cognitive decline. And perhaps most importantly, it is reimbursed by Medicare and all major payers.

How to Read the News: Part 5 of 5


Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

The purpose of the Brain Today blog is to distill the daily news about brain health and help the public understand the essential meaning of each article. Through time however, I have found myself clarifying the same themes over and over again. Five of these themes are explored in this five-part series “How to Read the News About Alzheimer’s and Dementia”.

How to Read the News About Alzheimer’s and Dementia - Part 5 “No Cure” is not Nearly as Bad as it Sounds

For some reason, journalists feel compelled to point out the fact that Alzheimer’s has no cure. The mere mention of this basic truth tends to cast a pall over the topic and suggests a direness that is not necessary. Diabetes has no cure; hypertension has no cure; multiple sclerosis has no cure; yet all of those diseases are reported in the press with optimism about treatment that never seems to follow Alzheimer’s disease.

I concede that available treatment for Alzheimer’s disease generally yields only modest effects and sometimes none at all. However, some patients respond quite well to treatment and physicians have no way of distinguishing responders from non-responders ahead of time. For this reason, it makes sense to get all AD patients on treatment as early as possible to optimize treatment efficacy for all.

Also, the realm of treatment goes beyond the pharmaceutical arena. Solid research shows that physical activity, a good diet, social engagement, an educated caregiver, intellectual stimulation, and perhaps certain supplements are components of a robust treatment plan that can slow progression of symptoms in many patients. Reading that a single component of treatment, say a certain drug, has an unimpressive impact on disease progression is not enough to conclude that treatment is worthless.

Finally, a major barrier to effective treatment is that we generally fail to diagnose AD in a timely manner. Most patients are diagnosed after several years of symptoms when significant brain damage has already occurred and treatment is unlikely to help. Certainly we cannot cure the disease at that late stage but an earlier intervention might delay it long enough to prevent the patient from becoming demented. New drugs in the FDA approval pipeline might halt it all together.

The bottom line is that stating, “AD has no cure”, obscures the fact that it can be treated with some degree of success, for many people, especially when diagnosed in an early stage. Many diseases have no known cure but we manage them in the medical system with a sense of purpose and optimism. We need to approach AD in a similar manner.

Here are the links to each other part of this series:
Part 1 of 5: Be Aware of the Author's Definition of AD
Part 2 of 5: Don't be Mislead by Data on Treatment Efficacy
Part 3 of 5: Common Assertions about Diagnostic Accuracy Hide Truth
Part 4 of 5: The Term "Dementia" Cannot be Interpreted Loosely

The Value of Memory Tests

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

In the news today you may read about the value of memory tests for identifying subtle memory loss at an early and more treatable stage. The findings are published in Neurology by a team of researchers at Oxford University.

In the study, the research team followed healthy volunteers for 20 years and assessed their memory at regular intervals. For those whose cognition eventually declined, the scientists were able to look back and identify specific, measurable signs of diminishing memory and language skills.

These findings are consistent with our understanding that many conditions that impair cognition, particularly Alzheimer's disease, follow a long course that slowly damages the brain. The findings are important because they speak to the potential for very accurate tests that detect subtle changes to facilitate much earlier intervention and better treatment results. Currently, most causes of dementia go undiagnosed for many years while unnecessary brain damage accumulates irreversibly.

The Most Overlooked Opportunity in the Field of Alzheimer’s Care

Contributed by: Dennis Fortier, President, Medical Care Corporation

We all know about the obvious problems associated with Alzheimer's disease (AD). The media carry daily stories about the aging of the population (nearly 10,000 baby boomers turning 65 each day).  We are also inundated with messages about how current medications seem to be minimally effective against this poorly understood disease. Certainly, our limited ability to treat a disease that affects a burgeoning, elderly population makes for dire headlines.

However, there is a third problem that seems to be commonly overlooked in this conversation.

Late Intervention: Both Problem and Opportunity
This third problem is less obvious than the aging population and minimally effective treatment, but solving it will greatly mitigate the impact of these more widely noted themes. The problem is the unacceptably late intervention that we practice against this progressive disease. We routinely diagnose AD near end-stage pathology.

There is a fair degree of variability from case to case but, on average, AD follows a 14-year course from the onset of subtle symptoms until death. This usually includes a 7-year period of mild cognitive impairment (MCI) during which patients remain independent and able to care for themselves. The MCI stage is typically followed by a 7-year period of worsening dementia. In most instances (95% of instances according to one study), AD is first diagnosed during the mild or moderate dementia stages. This correlates roughly to years 8 through 11 on the 14-year time line.

We are dealing with a progressive disease that ravages the brain with each passing year and, on average, we are not intervening with treatment until end-stage pathology and massive brain damage have occurred. Yes, we need better treatments, but we can improve outcomes meaningfully by treating earlier with the currently approved interventions.

Alas, earlier intervention is a sensible but slippery goal. This is because early-stage AD patients, those in the MCI stage, have only mild symptoms. In this way, they look to a physician precisely like the multitudes of "normally aging" patients who have accurately sensed a slowing of their word or name recall, and are needlessly worried about AD. As you might imagine, these two types of patients are difficult to distinguish from one another.

Major Challenge: Discernment of Healthy Patients from Unhealthy Patients
Since the chances are high that a 65-year old patient complaining of subtle memory decline does not have early stage AD, such concerns are usually not closely evaluated until symptoms worsen considerably. This has lead to the current practice of intervening only after the disease has progressed to the dementia stage when, by definition, the symptoms are quite pronounced.

Today, however, there are short neuropsychological assessments, scored with sophisticated computer algorithms, that accurately distinguish MCI from normal aging. These assessment tools perform an efficient traffic control function to escort the worried well out of the health care system, while retaining those with objectively measured deficits for a comprehensive diagnostic work-up. With such brief and inexpensive assessment tools, physicians can now intervene earlier and treat memory disorders like AD before unnecessary brain damage has occurred. Doing so will foster a major improvement in standards of care for Alzheimer's patients.

Education and Awareness: Next Opportunities for Better Care
In this regard, the major challenge to an immediate improvement in care becomes one of awareness and education for the public and for primary care physicians. This is difficult but perhaps more certain in its achievability than the more scientifically challenging process of fully understanding AD and developing treatment agents that will halt its progression.

We need to tackle this disease from all angles and getting an earlier start with intervention seems to be an immediately graspable approach that does not, in my opinion, get enough attention in the field.

Functional MRI may be useful in detecting early stage Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

We have seen much press about the promise of advanced tracers and binding agents that improve the ability of imaging technologies to identify signs of early stage Alzheimer's disease. Due to the popularity of the amyloid hypothesis, suggesting that beta amyloid plaques are a key culprit in Alzheimer's pathology, research on agents that bind to amyloid have been especially present in the recent literature.

A study now published in Neurology suggests that functional MRI might also be useful in detecting early signs of Alzheimer's disease. In a study conducted at Cleveland Clinic’s Lou Ruvo Center for Brain Health, a group of 69 cognitively healthy adults, some of whom were genetically at risk to develop Alzheimer’s disease, were evaluated. Functional MRI was used to measure the participant's brain activity during a series of recognition tasks and the results of the at-risk group were compared to the results of the others.

The results showed an increased activation of certain parts of the brain in at-risk individuals which may reflect a compensatory brain response by those in the earliest stages of Alzheimer’s disease. If so, fMRI could prove to be a key technology for earlier identification of and intervention against emerging Alzheimer's disease.

A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message and help the world.

Earlier Intervention Against AD Could Preserve Health and save Billions in Costs

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

One of the most respected researchers in the Alzheimer's field, Mark Sager at the University of Wisconsin in Madison, has published his group's latest findings in Alzheimer's and Dementia. They concluded that the costs of not screening for Alzheimer's and not providing caregiver support costs the nation billions of dollars in avoidable public health care expenditures.

This is not surprising given the well documented correlation between progression of AD symptoms and rising costs of care. The importance of this publication lies in the fact that it is another solid piece of research arguing for a more proactive approach to battling AD.

Buried in this study is another important finding that debunks the argument against screening for memory loss. While some have speculated that seeking signs of memory loss among the presumed healthy stirs up unnecessary angst about the specter of Alzheimer's disease. Angst they characterize as "not constructive" given that no cure for AD is at hand.

Contrarily, this study showed that many people diagnosed with AD were relieved. This finding is consistent with several smaller studies that have shown the same result. The take away is this: if our ability to manage the disease is improved through early diagnosis and the people who undergo memory assessment are happier to have done so, then the benefits of a proactive, early-intervention program are amplified.

If we can continue to tear down the argument against earlier intervention while demonstrating the health and economic benefits of doing so, we will be much more effective in managing this disease, even before a cure is found.

A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.